Get the Stockscreener App
13.09
7.21%
0.88
Pre-market:
13.00
-0.09
-0.69%
Eyepoint Pharmaceuticals Inc stock is traded at $13.09, with a volume of 1.51M.
It is up +7.21% in the last 24 hours and down -8.08% over the past month.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
See More
Previous Close:
$12.21
Open:
$12.2
24h Volume:
1.51M
Relative Volume:
1.47
Market Cap:
$902.26M
Revenue:
$46.02M
Net Income/Loss:
$-70.80M
P/E Ratio:
-7.1923
EPS:
-1.82
Net Cash Flow:
$-1.61M
1W Performance:
+9.27%
1M Performance:
-8.08%
6M Performance:
+91.94%
1Y Performance:
+11.31%
1-Day Range:
$11.92
$13.12
1-Week Range:
$11.55
$13.12
52-Week Range:
$3.91
$14.91
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Name
Eyepoint Pharmaceuticals Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
13.09 | 986.00M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Pharmaceuticals Inc Stock (EYPT) Latest News
EyePoint Announces Participation at Upcoming Investor Conferences - EyePoint Pharmaceuticals
EyePoint (NASDAQ: EYPT) to appear at Guggenheim, Stifel and Jefferies investor events - Stock Titan
Should you wait for a breakout in EyePoint Pharmaceuticals Inc.Market Sentiment Summary & Daily Profit Focused Screening - newser.com
What’s next for EyePoint Pharmaceuticals Inc. stock priceTrade Volume Summary & Fast Entry High Yield Tips - newser.com
Is EyePoint Pharmaceuticals Inc. stock ready for breakout2025 Support & Resistance & Risk Managed Investment Strategies - newser.com
Has EyePoint Pharmaceuticals Inc. formed a bullish divergenceJobs Report & Growth Oriented Trading Recommendations - newser.com
Is EyePoint Pharmaceuticals Inc. (PV3B) stock a buy before new product rollout - newser.com
Combining price and volume data for EyePoint Pharmaceuticals Inc.July 2025 Institutional & Fast Gain Stock Trading Tips - newser.com
EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholder returns have been stellar, earning 212% in 5 years - simplywall.st
Eyepoint Pharmaceuticals (EYPT) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Will EyePoint Pharmaceuticals Inc. stock split attract more investorsJuly 2025 Decliners & Fast Exit and Entry Strategy Plans - newser.com
EyePoint Pharmaceuticals Inc. stock outlook for YEARWeekly Market Report & Growth Focused Stock Pick Reports - newser.com
EyePoint Pharmaceuticals Inc Stock Analysis and ForecastCandlestick Pattern Analysis & Consistently Superior Profits - earlytimes.in
With 57% institutional ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) is a favorite amongst the big guns - Yahoo Finance
Will EyePoint Pharmaceuticals Inc. stock outperform growth indexesTrade Risk Report & Free High Return Stock Watch Alerts - newser.com
EyePoint Pharmaceuticals to Host Conference Call for Q3 2025 Financial Results on November 5, 2025 - Quiver Quantitative
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 - The Manila Times
EyePoint Pharmaceuticals (NASDAQ: EYPT) sets 8:30 a.m. ET call to discuss Q3 results - Stock Titan
Will EyePoint Pharmaceuticals Inc. stock see insider buyingJuly 2025 Momentum & Weekly High Momentum Picks - fcp.pa.gov.br
Is EyePoint Pharmaceuticals Inc. stock recession proof2025 Risk Factors & Verified Short-Term Trading Plans - fcp.pa.gov.br
Is EyePoint Pharmaceuticals Inc. stock a safe buy before earningsWeekly Stock Recap & Smart Money Movement Tracker - fcp.pa.gov.br
EyePoint Pharmaceuticals Completes US$150 Million Follow-On Equity Offering - Global Legal Chronicle
What drives EyePoint Pharmaceuticals Inc stock priceDouble Top/Bottom Patterns & Maximize Gains Professionally - earlytimes.in
Eyepoint Pharmaceuticals Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):